Treating Pediatric Patients With ALL - prIME Oncology
prIME Case
prIME Case

Treating Pediatric Patients With ALL

Best Practices for Incorporating Asparaginase

Not a member of My prIME? Join now for instant access.

Understand the current best practices for the use of asparaginase in treating pediatric patients with acute lymphoblastic leukemia (ALL) through this interactive clinical scenario that includes detailed descriptions of treatment decision-making strategies.

Interactive Presentation

Interactive Presentation

CME

CME

0.75 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Apr 19, 2019

Expiration Date

Apr 19, 2020

  • Similarities and differences among available asparaginase preparations
  • Use of asparaginase in treating pediatric ALL
  • Management of adverse events
  • Stephen E. Sallan, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Lynda M. Vrooman, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

This activity is designed to meet the educational needs of hematologists, pediatric hematologists, nurses, physician assistants, nurse practitioners, and other healthcare professionals who treat or manage patients with hematologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Create treatment strategies that optimize the use of asparaginase for ALL
  • Implement best practices to manage treatment-related adverse events (TRAEs) associated with the use of asparaginase

This educational activity is supported by a grant from Jazz Pharmaceuticals.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.75 hours

To contact Postgraduate Institute for Medicine, please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Sallan has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vrooman has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director) – worked on non–CME certified projects in the last 12 months supported by Pfizer
  • Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
  • Susan McKinney (editorial content reviewer) – no financial relationships

The PIM planners and managers have nothing to disclose.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.